# Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

> **NCT06393166** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 37 (estimated)

## Conditions studied

- Non-Resectable Pancreas Carcinoma

## Interventions

- **DRUG:** Sequential AG and mFOLFOX in Combination With Serplulimab Injection and Bevacizumab Injection

## Key facts

- **NCT ID:** NCT06393166
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-12-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393166, "Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06393166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*